Trials & Filings

Good Early Results for Celsion Breast Cancer Drug

Thermodox plus hyperthermia leads to 60% response rate in BCRCW

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Celsion Corp. has presented combined clinical study results from the company’s Phase I study and the Duke University-sponsored Phase I trial of ThermoDox plus hyperthermia in Breast Cancer Recurrences at the Chest Wall (BCRCW). The results were presented at the 2013 San Antonio Breast Cancer Conference.   The two similarly designed Phase I studies enrolled patients with highly resistant tumors found on the chest wall and who had progressed on previous therapy including chemotherapy, radia...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters